Palisade Bio Inc (PALI)
6.30
-0.16
(-2.48%)
USD |
NASDAQ |
May 17, 16:00
6.30
0.00 (0.00%)
After-Hours: 20:00
Palisade Bio Research and Development Expense (Quarterly): 2.214M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.214M |
| December 31, 2023 | 1.733M |
| September 30, 2023 | 1.742M |
| June 30, 2023 | 2.177M |
| March 31, 2023 | 1.241M |
| December 31, 2022 | 2.343M |
| September 30, 2022 | 1.928M |
| June 30, 2022 | 1.317M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.959M |
| December 31, 2021 | 0.80M |
| September 30, 2021 | 0.624M |
| June 30, 2021 | 0.314M |
| March 31, 2021 | 0.692M |
| December 31, 2020 | 0.785M |
| September 30, 2020 | 0.412M |
| June 30, 2020 | 0.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.314M
Minimum
Jun 2021
2.343M
Maximum
Dec 2022
1.246M
Average
1.10M
Median
Research and Development Expense (Quarterly) Benchmarks
| TG Therapeutics Inc | 32.72M |
| Protagenic Therapeutics Inc | 1.011M |
| Bio-Path Holdings Inc | 2.276M |
| Jaguar Health Inc | 4.312M |
| Finch Therapeutics Group Inc | 0.00 |